Investor Presentaiton
Company overview
Financial performance
Financial review
2022 priorities
Innovation: Pipeline overview
Novartis pipeline in Phase 2
Solid Tumors
Code
Name
AAA601
LutatheraⓇ
DRB436 Tafinlar® + Mekinist®
JDQ443 JDQ443
NIR178
NIR178, spartalizumab
NIS793 NIS793
TNO155 TNO155
Ad2AR inhibitor, PD1 inhibitor
TGFB inhibitor
Mechanism
Indication(s)
Radioligand therapy target SSTR GEPNET, pediatrics
BRAF inhibitor + MEK inhibitor
KRAS inhibitor
1L ES-SCLC
Glioblastoma
HGG/LGG, pediatrics
NSCLC (Combo)
Cancers
1L metastatic colorectal cancer
SHP2 inhibitor
Solid tumors (single agent)
Hematology
Appendix
Innovation: Clinical trials
References
Abbreviations
27 lead indications
Lead indication
Code
ABL001
Name
ScemblixⓇ
INC424 JakaviⓇ
LNP023 iptacopan
MBG453
sabatolimab
PHE885 PHE885
PKC412 Rydapt®
Mechanism
BCR-ABL inhibitor
JAK1/2 inhibitor
CFB inhibitor
TIM3 antagonist
BCMA cell therapy
Multi-targeted kinase inhibitor
Indication(s)
Chronic myeloid leukemia, 2L, pediatrics
Acute GVHD, pediatrics
Immune thrombocytopenia
Unfit acute myeloid leukaemia
Acute myeloid leukaemia, maintenance
4L multiple myeloma
Acute myeloid leukemia, pediatrics
Chronic GVHD, pediatrics
Cardio-renal
Mechanism
CD40 inhibitor
Indication(s)
Lupus nephritis Type 1 diabetes mellitus
Atrial fibrillation
Membranous nephropathy
Obesity related diseases.
Immunology
Code
Code
Name
Mechanism
Indication(s)
AIN457
CFZ533
Cosentyx®
iscalimab
IL17A inhibitor
CD40 inhibitor
Lichen planus
Sjögren's
Liver Tx
Hidradenitis suppurativa
Name
CFZ533 iscalimab
HSY244 HSY244
LNP023 iptacopan
MBL949 MBL949
CFB inhibitor
CMK389 CMK389
DFV890 DFV890
IL-18 inhibitor
NLRP3 inhibitor
LNA043
LNA043
ANGPTL3 agonist
Atopic dermatitis
Familial cold auto-inflammatory syndrome
Knee osteoarthritis
Osteoarthritis (combos)
Osteoarthritis
Name
Mechanism
LOU064 remibrutinib
LRX712 LRX712
BTK inhibitor
Sjögren's
Osteoarthritis
Anti-inflammatory
Acne
Colitis ulcerative
NLRC4-GOF indications
Hidradenitis suppurativa
Hidradenitis suppurativa
LYS006 LYS006
MAS825 MAS825
MHV370 MHV370
VAY736 ianalumab
BAFF-R inhibitor
Neuroscience
Code
Name
ADPT06 ADPT06
sotuletinib
Mechanism
BLZ945
CSF-1R inhibitor
DLX313
LMI070
DLX313 (UCB0599)
branaplam
Alpha-synuclein Inhibitor
mRNA splicing modulator
MIJ821 MIJ821
NR2B negative allosteric
modulator
1. Gyroscope acquisition
Sjögren's
Sjögren's
Systemic lupus erythematosus
Indication(s)
Cognitive impairment
Amyotrophic lateral sclerosis
Parkinson's disease
Huntington's disease
Mixed connective tissue disease
Autoimmune hepatitis
Major depressive disorder with acute suicidal ideation or behavior
Others
Code
Global Health
KAE609 cipargamin
KAF156 ganaplacide
LXE408 LXE408
SEG101 Adakveo®
Respiratory & Allergy
CMK389 CMK389
QBW251 icenticaftor
QMF149 AtecturaⓇ
Ophthalmology
LKA651 LKA651
PPY9881 PPY988
SAF312 libvatrep
UNR844 UNR844
PfATP4 inhibitor
Proteasome inhibitor
P-selectin inhibitor
IL-18 inhibitor
CFTR potentiator
Combo
EPO inhibitor
Gene therapy
TRPV1 antagonist
Reduction of disulfide bonds
Indication(s)
Malaria, severe
Malaria, uncomplicated
Visceral leishmaniasis
Malaria, uncomplicated
Sickle cell disease, pediatrics
Pulmonary sarcoidosis
Chronic obstructive pulmonary disease Bronchiectasis
Asthma, pediatrics
Diabetic retinopathy
Geographic atrophy
Chronic ocular surface pain
Presbyopia
40 Investor Relations | Q2 2022 Results
U NOVARTIS | Reimagining MedicineView entire presentation